Navigation Links
AMICAS Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2007
Date:2/28/2008

arter; the length of sales and delivery cycles; the deferral and/or realization of deferred software license and system revenues according to contract terms; the timing, cost and success or failure of current and new product and service introductions and product upgrade releases; potential patent infringement claims against AMICAS and the related defense costs; the ability of AMICAS to comply with all government laws, rules and regulations; and other risks affecting AMICAS' businesses generally and as set forth in AMICAS' most recent filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" of our most recent annual report on Form 10-K, and subsequent quarterly reports on Form 10-Q. All forward- looking statements in this release are qualified by these cautionary statements and are made only as of the date of this release. AMICAS is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise. The financial statements and information as of, and for the period ended, December 31, 2007 contained in this press release are subject to review by the Company's independent registered public accounting firm.

CONTACT: Lisa Gould, Investor Relations

617.779.7892

lgould@amicas.com

Condensed Consolidated Balance Sheets

(in thousands, except share data)

December 31, December 31,

2007 2006

Assets

Current assets:

Cash and cash equivalents $8,536 $7,331

Marketable debt securities 67,071 64,436

Accounts receivable, net of allowances of $231

and $1,050, respectively
'/>"/>

SOURCE AMICAS, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. AMICAS Schedules Fourth Quarter and 2007 Year End Earnings Results Conference Call
2. AMICAS to Present at UBS Global Healthcare Services Conference
3. MedQuest Standardizes on AMICAS Vision Series PACS
4. AMICAS Solutions Closing the Loop in Radiology Communications
5. AMICAS Transforms Critical Results Notification with RadStream
6. AMICAS Launches Vision Reach 2.0, a Tool to Help Radiology Businesses Grow
7. Webcast Alert: AMICAS, Inc. Announces 3rd Quarter 2007 Earnings Conference Call
8. Radiology Ltd. Chooses AMICAS as End-to-End Solutions Provider
9. AMICAS Schedules Third Quarter Earnings Call
10. AMICAS to Present at William Blair & Company Small Cap Growth Stock Conference
11. AMICAS Hosts Complimentary DRA Education Session Featuring Timothy Trysla
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2008)...swire-USNewswire/ -- The American Heart,Associatio... Lewis,Achievement Award, the association,s highes...ard was established in 2000, to recognize and hono...edical journalists who have documented,the conside...ease and,stroke. This career achievement award was...
(Date:7/23/2008)...23 /PRNewswire-USNewswire/ -- The Alameda County,P...ly 24-26 at the Oakland,Marriott to address the so...in individuals from low-income and communities of ...s and counties will attend. Place Matters,is a nat... and Economic,Studies, Health Policy Institute and...
(Date:7/23/2008)...e Dangerous for Morbidly Obese Women? ,As the ...are consulting plastic surgeons for breast reducti...ad been thought to have higher complication rates....e as safe to perform large-volume breast reduction...Study title: Breast Reduction: Safe in the Morbidl...
(Date:7/23/2008)...23 /PRNewswire-USNewswire/ -- The New Jersey,Hospi...t Safety has,received a planning grant for $199,50...o develop a proposal for improving the quality of,...termine over the next six months whether New,Jerse... Quality initiative,which is focused on lifting t...
Breaking Medicine News(10 mins):Health News:Alameda County Hosts National Initiative to Reduce Health Disparities 2
...ason some adolescents experience depression could ...d nearly 30 adolescents between ages 13 to 18, hal...disorder. Magnetic resonance imaging was performed...ft and right hippocampus. The results indicated th...
...and women, 60 to 96 years old, who suffered from l...sarcopenia.// The individuals trained for eight to... strength ranging from 113 percent to 174 percent....uscle loss by incorporating a weight training rout...
...u fat. In an editorial published in the Jan. 10 is...hwestern University researchers stress the need //...ty in the United States by studying how loss of sl...ys that control appetite, food intake and energy e...
...ng been associated with cancers, fibrosis and othe...searchers say // exposure to asbestos may lay the ...rheumatoid arthritis and multiple sclerosis. Resea..., which is known to be polluted by asbestos. They ...
Other Medicine News:Health News:Sleeping Less May be related to Weight Gain 2
(Date:7/23/2008)...de BioPharmaceutics, Inc.,an emerging biopharmace...esults demonstrating the utility of their lead dru...ronic blood disorder paroxysmal nocturnal,hemoglob...ed at the XXII,International Complement Workshop i...ly treatment currently available for PNH patients ...
(Date:7/23/2008)...rotein Therapeutics that Modulate Altern...ss., July 23 /- Taligen Therapeutics ...growth plan with the,appointment of Abbie Celniker...ishment of its headquarters in Cambridge, Mass. Dr...nder of the company who remains president., Under...
(Date:7/22/2008)...er 293-patient European, trial -, http://www.cr... MONTREAL, July 22 / CryoCa...therapy products to treat cardiac,arrhythmias, tod...m three,European study centers using the Company,s...lier today in the Journal of the American College ...
(Date:7/22/2008)...t Initiative bring MJFF,s,current active industry ...09, NEW YORK, July 22 /PRNewswire-USNewswire/ -- ...ormative treatments and a cure for Parkinson,s,dis...s Research has awarded,$2.7 million in total fundi... granted under MJFF,s Therapeutics Development Ini...
Breaking Medicine Technology:InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) 2Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 2Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 3CryoCath Arctic Front(R) Results Published in JACC 2CryoCath Arctic Front(R) Results Published in JACC 3Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 2Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 3Vaginal progesterone gel may improve infant outcomes and 2659 1Vaginal progesterone gel may improve infant outcomes and 2659 2Vaginal progesterone gel may improve infant outcomes and 2659 3Vaginal progesterone gel may improve infant outcomes and 2659 4Study Supports Change to Prostate Cancer Biopsy 2657 1Study Supports Change to Prostate Cancer Biopsy 2657 2Study Supports Change to Prostate Cancer Biopsy 2657 3Angel Flight West Recognizes Colorado Pilots and Supporters at AFW 24th Anniversary Awards 2655 1Angel Flight West Recognizes Colorado Pilots and Supporters at AFW 24th Anniversary Awards 2655 2Study Determines Breast Specific Gamma Imaging Has Higher Specificity Than MRI in Patients With Equivocal Mammograms 2652 1Study Determines Breast Specific Gamma Imaging Has Higher Specificity Than MRI in Patients With Equivocal Mammograms 2652 2Study Determines Breast Specific Gamma Imaging Has Higher Specificity Than MRI in Patients With Equivocal Mammograms 2652 3
...I Pharma, Inc.,(Nasdaq:MOGN), a biopharmaceutical ...provided highlights of data presentations made,dur... (ASCO) Annual,Meeting. Dacogen (decitabine) for I... the presentation of efficacy data in older,patien...ity,observed in patients with refractory acute lym...
...2007 - Synta,Pharmaceuticals Corp., (NASDAQ: SNTA)...g, developing, and commercializing small,molecule ...nounced,it will hold a conference call at 2:30 p.m... be presented at the annual meeting of the,America...Illinois,this morning., The conference call will b...
Other Medicine Technology:MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 2MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 3MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 4MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 5MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 6MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 7MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 8MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 9MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 10
BD Vacutainer® Fluoride Tubes - Glass
BD Vacutainer® Specialty Tubes - Trace Element - Glass
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients.
BD Vacutainer® Plus Plastic Serum Tubes have spray-coated silica and are used for serum determinations in chemistry, serology, and immunohematology.
Medicine Products: